[1]赵德善.放射性核素标记生长抑素类似物在淋巴瘤中的应用[J].国际放射医学核医学杂志,2004,28(5):206-209.
　ZHAO De-shan.The role of radionuclide-labeled somatostatin analogues in lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(5):206-209.
点击复制

放射性核素标记生长抑素类似物在淋巴瘤中的应用(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
28
期数:
2004年第5期
页码:
206-209
栏目:
核医学
出版日期:
1900-01-01

文章信息/Info

Title:
The role of radionuclide-labeled somatostatin analogues in lymphoma
作者:
赵德善
030001 太原, 山西医科大学第一医院核医学科
Author(s):
ZHAO De-shan
Department of Nuclear Medicine, No.1 Hospital of Shanxi Medical University, Taiyuan 030001, China
关键词:
生长抑素类似物; 生长抑素受体; 奥曲肽; 淋巴瘤; 生长抑素受体显像; 治疗
Keywords:
somatostatin analogues; somatostatin receptors; octreotide; lymphoma; somatostatin receptors scintigraphy; treatment
分类号:
R817.4;R817.5
摘要:
生长抑素类似物如奥曲肽、depreotide等与生长抑素受体作用时间长、亲和力高,并可被放射性核素标记,用于肿瘤的生长抑素受体显像和治疗。淋巴瘤细胞表达该受体,因此可利用生长抑素受体对其进行显像和治疗。大量临床和实验研究均表明,放射性核素标记生长抑素类似物的生长抑素受体显像可对淋巴瘤进行诊断、分期、治疗和预后的评价,也可作为常规影像学显像、67Ga和PET显像诊断、评价淋巴瘤的一种有力补充。而在淋巴瘤治疗中的应用应当慎重,如何能获得最佳治疗效果而又将其副作用减小到最低程度是今后研究的主要课题之一。
Abstract:
Somatostatin analogues, such as octreotide, depreotide and so on, having long-time and high affinity with somatostatin receptors(SSTR) and labeled by radionuclides, can be used in SSTR scintigraphy and treatment of tumors expressing SSTR. Moreover, Lymphoma express SSTR(SSTR2 and SSTR3). A series of clinical and experimental results showed SSTR scintigraphy is an interesting way to evaluate the diagnosis, staging, treatment and prognosis of lymphoma, and a supplemental tool of diagnosing and judging lymphoma with conventional X-rays imaging, 67Ga and PET. Whereas, the application of radionuclide-labeled somatostatin analogues in treatment of lymphoma should be cautiously performed. Recently it is a concerned question how the patients suffering from lymphoma can have the most profits and the least side-effects from the treatment of radionuclide-labeled somatostatin analogues.

参考文献/References:

1 Cascini GL,Cuccurullo V,Rambaldi PF,et al.Immunological imaging using tagged octreotide[J].Minerva Endocrinol, 2001,26(3):129-133.
2 Patel YC.Somatostatin and its receptors family[J].Frontier Neu-roendocrinol,1999,20(3):157-198.
3 Schonbrunn A.Somatostatin receptors present knowledge and future directions[J].Annal Oncol,1999,10(Suppl 2):s17-s21.
4 Feniuk W,Jarvie E,Luo J,et al.Selective somatostatin sst2 receptor blockade with the novel cyclic octapeptide,CYN-154806[J].Neuropharmacology,2000,39(8):1443-1450.
5 Reubi JC,Waser B,van Hagen M,et al.In vitro and in vivo detection of somatostatin receptors in human malignant lymphomas[J].Int J Cancer,1992,50(6):895-900.
6 Dalm VA,Hofland LJ,Mooy CM,et al.Somatostatin receptors inmalignant lymphomas:targets for radiotherapy[J].J Nucl Med,2004,45(1):8-16.
7 Virgolini I,Traub T,Novotny C,et al.New trends in peptide receptor radioligands[J].Q J Nucl Med,2001,45(2):153-159.
8 Decristoforo C,Mather SJ,Cholewinski W,et al.99mTc-EDDA/HYNIC-TOC:a new 99mTc-labelled radiopharmaceutical for somatostatin receptor-positive tumors:first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives[J].Eur J Nucl Med,2000,27(9):1318-1325.
9 Gabriel M,Decristoforo C,Donnemiller E,et al.An intrapatientcomparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-oc-treotide for diagnosis of somatostatin receptor-expressing tumors[J].J Nucl Med,2003,44(5):708-716.
10 Decristoforo C,Melendez-Alafort L,Sosabowski JK,et al.99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors:preclinical evaluation and comparison with In-oc-treotide[J].J Nucl Med,2000,41(6):1114-1119.
11 Virgolini I,Leimer M,Handmaker H,et al.Somatostatin receptor subtype specificity and in vivo binding of a novel tumor tracer,99mTc-P829[J].Cancer Res,1998,58(9):1850-1859.
12 Machac J,Krynyckyi B,Kim C.Peptide and antibody imaging in lung cancer[J].Semin Nucl Med,2002,32(4):276-292.
13 Lipp RW,Schnedl WJ,Aglas F,et al.Visualization of non-Hodgkin’s lymphoma by high dosed somatostatin receptor specific scintigraphy and extended single photon emission tomography[J].Acta Med Austriaca,1999,26(3):105-108.
14 Li S,Kurtaran A,Li M,et al.111In-DOTA-dPhe1-Tyr3-octreotide,111In-DOTA-lanreotide and 67Ga citrate scintigraphy for visualisation of extranodal marginal zone B-cell lymphoma of the M ALT type:a comparative study[J].Eur J Nucl Med Mol Imag,2003,30(8):1087-1095.
15 Raderer M,Traub T,Formanek M,et al.Somatostatin-receptor scintigraphy for staging and follow-up of patients with extraintestinal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT)-type[J].Br J Cancer,2001,85(10):1462-1466.
16 van den Anker-Lugtenburg PJ,Lowenberg B,Lamberts SW,et al.The relevance of somatostatin receptor expression in malignant lym-phomas[J].Metabolism,1996,45(8 Suppl 1):96-97.
17 Lipp RW,Silly H,Ranner G,et al.Radiolabeled octreotide for the demonstration of somatostatin receptors in malignant lymphoma and lymphadenopathy[J].J Nucl Med,1995,36(1):13-18.
18 Reubi JC,Schaer JC,Wenger S,et al.SST3-selective potent pep-tidic somatostatin receptor antagonists[J].Proc Natl Acad Sci USA,2000,97(25):13973-13978.

相似文献/References:

[1]段炼,李险峰.甲状腺相关眼病与生长抑素受体显像[J].国际放射医学核医学杂志,2005,29(3):108.
　DUAN Lian,LI Xian-feng.Thyroid associated ophthalmopathy and somatostatin receptor scintigraphy[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(5):108.
[2]王利伟,王自正,顾建平,等.孤立性肺结节的影像学研究进展[J].国际放射医学核医学杂志,2005,29(6):248.
　WANG Li-wei,WANG Zi-zheng,GU Jian-ping,et al.The development in imaging of the solitary pulmonary nodules[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(5):248.
[3]向艳,夏劲松.生长抑素类似物及其标记核素[J].国际放射医学核医学杂志,2002,26(1):21.
　XIANG Yan,XIA Jin-song.Recent development of radio-labeled somatostatin analogues as receptor image agent[J].International Journal of Radiation Medicine and Nuclear Medicine,2002,26(5):21.
[4]武鸿文,管昌田.99mTc标记生长抑素类似物作为受体显像剂及其特性研究[J].国际放射医学核医学杂志,1998,22(4):158.

备注/Memo

备注/Memo:
收稿日期:2004-04-10。
更新日期/Last Update: 1900-01-01